Development of therapeutic siRNAs for pachyonychia congenita

Frances J. D. Smith, Robyn P. Hickerson, Jane M. Sayers, Robert E. Reeves, Christopher H. Contag, Devin Leake, Roger L. Kaspar, W. H. Irwin McLean

    Research output: Contribution to journalArticle

    55 Citations (Scopus)

    Abstract

    Pachyonychia congenita (PC) is an autosomal-dominant keratin disorder where the most painful, debilitating aspect is plantar keratoderma. PC is caused by mutations in one of four keratin genes; however, most patients carry K6a mutations. Knockout mouse studies suggest that ablation of one of the several K6 genes can be tolerated owing to compensatory expression of the others. Here, we have developed potent RNA interference against K6a as a paradigm for treating a localized dominant skin disorder. Four small interfering RNAs (siRNAs) were designed against unique sequences in the K6a 3'-untranslated region. We demonstrated near-complete ablation of endogenous K6a protein expression in two keratinocyte cell lines, HaCaT and NEB-1, by transient transfection of each of the four K6a siRNAs. The siRNAs were effective at very low, picomolar concentrations. One potent lead K6a inhibitor, which was highly specific for K6a, was tested in a mouse model where reporter gene constructs were injected intradermally into mouse paw and luciferase activity was used as an in vivo readout. Imaging in live mice using the Xenogen IVIS system demonstrated that the K6a-specific siRNA strongly inhibited bicistronic K6a-luciferase gene expression in vivo. These data suggest that siRNAs can specifically and very potently target mutated genes in the skin and support development of these inhibitors as potential therapeutics.

    Original languageEnglish
    Pages (from-to)50-58
    Number of pages9
    JournalJournal of Investigative Dermatology
    Volume128
    Issue number1
    DOIs
    Publication statusPublished - Jan 2008

    Cite this

    Smith, F. J. D., Hickerson, R. P., Sayers, J. M., Reeves, R. E., Contag, C. H., Leake, D., ... McLean, W. H. I. (2008). Development of therapeutic siRNAs for pachyonychia congenita. Journal of Investigative Dermatology, 128(1), 50-58. https://doi.org/10.1038/sj.jid.5701040
    Smith, Frances J. D. ; Hickerson, Robyn P. ; Sayers, Jane M. ; Reeves, Robert E. ; Contag, Christopher H. ; Leake, Devin ; Kaspar, Roger L. ; McLean, W. H. Irwin. / Development of therapeutic siRNAs for pachyonychia congenita. In: Journal of Investigative Dermatology. 2008 ; Vol. 128, No. 1. pp. 50-58.
    @article{e04074f2654a45c8811c69b5856592b7,
    title = "Development of therapeutic siRNAs for pachyonychia congenita",
    abstract = "Pachyonychia congenita (PC) is an autosomal-dominant keratin disorder where the most painful, debilitating aspect is plantar keratoderma. PC is caused by mutations in one of four keratin genes; however, most patients carry K6a mutations. Knockout mouse studies suggest that ablation of one of the several K6 genes can be tolerated owing to compensatory expression of the others. Here, we have developed potent RNA interference against K6a as a paradigm for treating a localized dominant skin disorder. Four small interfering RNAs (siRNAs) were designed against unique sequences in the K6a 3'-untranslated region. We demonstrated near-complete ablation of endogenous K6a protein expression in two keratinocyte cell lines, HaCaT and NEB-1, by transient transfection of each of the four K6a siRNAs. The siRNAs were effective at very low, picomolar concentrations. One potent lead K6a inhibitor, which was highly specific for K6a, was tested in a mouse model where reporter gene constructs were injected intradermally into mouse paw and luciferase activity was used as an in vivo readout. Imaging in live mice using the Xenogen IVIS system demonstrated that the K6a-specific siRNA strongly inhibited bicistronic K6a-luciferase gene expression in vivo. These data suggest that siRNAs can specifically and very potently target mutated genes in the skin and support development of these inhibitors as potential therapeutics.",
    author = "Smith, {Frances J. D.} and Hickerson, {Robyn P.} and Sayers, {Jane M.} and Reeves, {Robert E.} and Contag, {Christopher H.} and Devin Leake and Kaspar, {Roger L.} and McLean, {W. H. Irwin}",
    year = "2008",
    month = "1",
    doi = "10.1038/sj.jid.5701040",
    language = "English",
    volume = "128",
    pages = "50--58",
    journal = "Journal of Investigative Dermatology",
    issn = "0022-202X",
    publisher = "Nature Publishing Group",
    number = "1",

    }

    Smith, FJD, Hickerson, RP, Sayers, JM, Reeves, RE, Contag, CH, Leake, D, Kaspar, RL & McLean, WHI 2008, 'Development of therapeutic siRNAs for pachyonychia congenita', Journal of Investigative Dermatology, vol. 128, no. 1, pp. 50-58. https://doi.org/10.1038/sj.jid.5701040

    Development of therapeutic siRNAs for pachyonychia congenita. / Smith, Frances J. D.; Hickerson, Robyn P.; Sayers, Jane M.; Reeves, Robert E.; Contag, Christopher H.; Leake, Devin; Kaspar, Roger L.; McLean, W. H. Irwin.

    In: Journal of Investigative Dermatology, Vol. 128, No. 1, 01.2008, p. 50-58.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Development of therapeutic siRNAs for pachyonychia congenita

    AU - Smith, Frances J. D.

    AU - Hickerson, Robyn P.

    AU - Sayers, Jane M.

    AU - Reeves, Robert E.

    AU - Contag, Christopher H.

    AU - Leake, Devin

    AU - Kaspar, Roger L.

    AU - McLean, W. H. Irwin

    PY - 2008/1

    Y1 - 2008/1

    N2 - Pachyonychia congenita (PC) is an autosomal-dominant keratin disorder where the most painful, debilitating aspect is plantar keratoderma. PC is caused by mutations in one of four keratin genes; however, most patients carry K6a mutations. Knockout mouse studies suggest that ablation of one of the several K6 genes can be tolerated owing to compensatory expression of the others. Here, we have developed potent RNA interference against K6a as a paradigm for treating a localized dominant skin disorder. Four small interfering RNAs (siRNAs) were designed against unique sequences in the K6a 3'-untranslated region. We demonstrated near-complete ablation of endogenous K6a protein expression in two keratinocyte cell lines, HaCaT and NEB-1, by transient transfection of each of the four K6a siRNAs. The siRNAs were effective at very low, picomolar concentrations. One potent lead K6a inhibitor, which was highly specific for K6a, was tested in a mouse model where reporter gene constructs were injected intradermally into mouse paw and luciferase activity was used as an in vivo readout. Imaging in live mice using the Xenogen IVIS system demonstrated that the K6a-specific siRNA strongly inhibited bicistronic K6a-luciferase gene expression in vivo. These data suggest that siRNAs can specifically and very potently target mutated genes in the skin and support development of these inhibitors as potential therapeutics.

    AB - Pachyonychia congenita (PC) is an autosomal-dominant keratin disorder where the most painful, debilitating aspect is plantar keratoderma. PC is caused by mutations in one of four keratin genes; however, most patients carry K6a mutations. Knockout mouse studies suggest that ablation of one of the several K6 genes can be tolerated owing to compensatory expression of the others. Here, we have developed potent RNA interference against K6a as a paradigm for treating a localized dominant skin disorder. Four small interfering RNAs (siRNAs) were designed against unique sequences in the K6a 3'-untranslated region. We demonstrated near-complete ablation of endogenous K6a protein expression in two keratinocyte cell lines, HaCaT and NEB-1, by transient transfection of each of the four K6a siRNAs. The siRNAs were effective at very low, picomolar concentrations. One potent lead K6a inhibitor, which was highly specific for K6a, was tested in a mouse model where reporter gene constructs were injected intradermally into mouse paw and luciferase activity was used as an in vivo readout. Imaging in live mice using the Xenogen IVIS system demonstrated that the K6a-specific siRNA strongly inhibited bicistronic K6a-luciferase gene expression in vivo. These data suggest that siRNAs can specifically and very potently target mutated genes in the skin and support development of these inhibitors as potential therapeutics.

    U2 - 10.1038/sj.jid.5701040

    DO - 10.1038/sj.jid.5701040

    M3 - Article

    VL - 128

    SP - 50

    EP - 58

    JO - Journal of Investigative Dermatology

    JF - Journal of Investigative Dermatology

    SN - 0022-202X

    IS - 1

    ER -

    Smith FJD, Hickerson RP, Sayers JM, Reeves RE, Contag CH, Leake D et al. Development of therapeutic siRNAs for pachyonychia congenita. Journal of Investigative Dermatology. 2008 Jan;128(1):50-58. https://doi.org/10.1038/sj.jid.5701040